Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S *et al*' by Yang *et al*

We are grateful for the interest in our work¹ shown by Drs Yang and Liang. In their correspondence regarding this work,² they raise concerns about (1) the association between anti-Ro52 autoantibodies and interstitial lung disease (ILD) in juvenile polymyositis (JPM) and juvenile connective tissue disease–myositis (JCTM), (2) the appropriateness of adjusting for duration of follow-up instead of length of time from onset to diagnosis and (3) the lack of statistical power to draw some conclusions.

First, as the prevalence of ILD between anti-Ro52-positive and anti-Ro52-negative patients was not statistically significant in the JPM and JCTM subgroups, we agree that larger studies will be necessary to confirm these tentative associations.

Second, as shown in table 2, the time from onset to diagnosis was very similar in anti-Ro52-positive (0.55 years) and anti-Ro52-negative patients (0.75 years, $p=0.3$). In contrast, the duration of follow-up trended towards being longer in anti-Ro52-negative patients (6.0 vs 4.3 years, $p=0.09$). For this reason, we chose to include duration of follow-up as a covariate in the multivariate analysis.

Third, the number of anti-Ro52 patients was large enough to detect highly significant differences in the multivariate analysis. For example, the prevalence of ILD in anti-Ro52-positive patients was 36%, while it was just 4% in anti-Ro52-negative patients, independent of the duration of follow-up, year of onset and the presence of myositis-specific autoantibodies ($p<0.001$). The low number of anti-Ro52-positive patients in some of the autoantibody groups did not affect these key findings.

Sara Sabbagh,¹ Iago Pinal Fernandez,¹ Frederick W Miller,² Lisa G Rider,² Andrew Lee Mammen¹

¹Muscle Disease Unit, Laboratory of Muscle Stem Cells and Gene Expression, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA

²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences/National Institutes of Health/Department of Health and Human Services, Bethesda, Maryland, USA

Correspondence to Dr Andrew Lee Mammen, NIAMS/NIH, Bethesda, MD 20892, USA; andrew.mammen@nih.gov

Handling editor Josef S Smolen

Contributors All authors approved this manuscript.

Funding This study was funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (<http://dx.doi.org/10.13039/1000000069>) and the National Institute of Environmental Health Sciences (<http://dx.doi.org/10.13039/1000000066>).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Sabbagh S, Pinal Fernandez I, Miller FW, *et al*. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2019-215693

Received 30 May 2019

Revised 3 June 2019

Accepted 4 June 2019

► <http://dx.doi.org/10.1136/annrheumdis-2019-215678>

Ann Rheum Dis 2019;0:1. doi:10.1136/annrheumdis-2019-215693

REFERENCES

- 1 Sabbagh S, Pinal-Fernandez I, Kishi T, *et al*. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. *Ann Rheum Dis* 2019. doi:10.1136/annrheumdis-2018-215004. [Epub ahead of print: 24 Apr 2019].
- 2 Yang Z, Liang Y. Response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh *et al*. *Ann Rheum Dis* 2019. doi:10.1136/annrheumdis-2019-215678. [Epub ahead of print: 16 May 2019].